Real-world effectiveness and safety of dapagliflozin therapy added to a GLP1 receptor agonist in patients with type 2 diabetes

详细信息    查看全文

• 作者：J.J. Gorgojo-Martí ; nez ; ^{jjgorgojo@fhalcorcon.es} ; C. Serrano-Moreno ^{cserranom@fhalcorcon.es} ; A. Sanz-Velasco ^{asanzv@fhalcorcon.es} ; G. Feo-Ortega ^{gfeo@gmail.com} ; F. Almodó ; var-Ruiz ^{falmodovar@fhalcorcon.es}
• 关键词：GLP1 receptor agonist ; SGLT-2 inhibitor ; Type 2 diabetes
• 刊名：Nutrition, Metabolism and Cardiovascular Diseases
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：27
• 期：2
• 页码：129-137
• 全文大小：508 K
• 卷排序：27

文摘

Real-world effect of dapagliflozin in type 2 diabetic patients and background GLP-1 receptor agonist therapy is evaluated. Dapagliflozin significantly decreases A1C and weight in patients treated with GLP-1 receptor agonists. Greater reductions in A1C and weight are observed in patients without background GLP1 receptor agonist therapy.